The present invention provides a method of enhancing an immune response to a vaccine using variant forms of anti-CTLA-4 antibodies with enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
展开▼